Cathy Russell

Senior Medical Science Liaison; PSMA PET/CT; Prostate Cancer; SLNB; lymphatic mapping; Theranostics; Radioligand Therapy

[Cathy Russell @CathyRusGil]

@LandLover56 My old vacuum!

[COSM @__COSM]

Join Dr. Stephen Y. Lai in collaboration with AHNS for a Clinical Trial Investigators Meeting on sentinel lymph node biopsy vs. elective neck dissection for early-stage oral cavity cancer.
Complimentary food & beverages provided!
#AHNS2024 #oncology #sentinellymphnodebiopsy
#Ad

[Telix Pharmaceuticals @TelixPharma]

Telix partners with @CardinalHealth for the global clinical supply of actinium-225 (Ac-225).​

Alpha therapies are widely regarded as the next generation of radiopharmaceuticals and a priority focus area for Telix’s therapeutic pipeline expansion.​

More: https://t.co/hk5lWfLVRX

[Louise Emmett @drlouiseemmett]

ENZA-p trial @TheLancetOncol
https://t.co/OSJ6FskZDd
Enzalutamide + adaptive-dosed (2 or 4) 177 Lu-PSMA617 vs enza alone in mCRPC.
Biomarker guided combination therapy works!
Better response depth/duration with no added tox. @ANZUPtrials @TrialsCentre @MovemberAUS @SVHSydney

[Arun Azad @AzadOncology]

Pleased to share our latest work published in @UrolOncol focusing on precision medicine in #ProstateCancer

Link 👇
https://t.co/D1mbFYyyAY

@anis_a_hamid @ChrisSweens1
@PeterMacRes

[UCL Head & Neck Academic Centre @UCL_HNAC]

📣 Shout-out Saturday

@UCL_HNAC are expanding the academic work and welcome all experience and expertise that @ClareSchilling will bring to our team

#SchillingSquad
@WomenSurgeonsUK @BAHNOOfficial @SurgeryWomen @uclmedsoc @uclcancer @uclh

[Ken Herrmann @ProfKHerrmann]

Super informative Feature in Nature. The business component of theranostics. ⁦#theranostics @CzerninJohannes⁩ ⁦@DrMHofman⁩⁦@stefanofanti4⁩⁦@JournalofNucMed⁩ The radiopharmaceutical renaissance: radiating hope in cancer therapy https://t.co/RFnqCrZIVq

[Cathy Russell @CathyRusGil]

@AvendaHealth How does this compare to or complement PSMA PET/CT?

[Daniel Castellano @cdanicas]

177Lu-PSMA therapy in metastatic prostate cancer: an updated review of prognostic and predictive biomarkers - ScienceDirect https://t.co/MpZAHSKi2y

[AO CMF @AOCMF_official]

🆕We are excited to open applications for the first global cohort of the Global Oral Cancer Diploma.
👉Secure your spot by applying today and save 20% on your tuition fee!
📍 Global
🔊 English
🔗 https://t.co/GvAdGfJrc4

[SNMMI @SNM_MI]

The Journal of Nuclear Medicine outlines the future of #theranostics in #neurooncology: https://t.co/jPhcQfaVyY

#NuclearMedicine @JournalofNucMed

[European Urology Oncology @EurUrolOncol]

Throwback Thursday: When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials

https://t.co/Qf3nrSy5zQ

@EAntonarakis @DanielPetrylak

#UroSoMe #ProstateCancer #Medtwitter

[GU Cast | Urology podcast! @gu_onc]

Free webinar on #PSMA #theranostics with @PCFnews @pros_tic @ICIS_News and GU Cast. More details here

[Yüksel Ürün @DrYukselUrun]

In our recently published article, we discussed this topic: #IlgınAkbıyık-MD
🧬One key question is that the efficacy of PARP inhibitors (PARPi) is not the same for all genetic alterations.
🧬🧬Secondly, with current methods, it's challenging to assert that we can accurately detect all these alterations.
🧬🧬🧬A third point is that, especially in countries where access to PARP inhibitors isn't an issue, we use ARPIs during the hormone-sensitive phase. This makes it less likely to find ARPI-naive patients for PARPi-ARPI combination therapy in the castration-resistant phase.
@futuresciencegp @OncoAlert @APCCC_Lugano @PCFnews @ASCO @myESMO @isliquidbiopsy @MCristofanill @TumorBoardTues @AnkaraUni @Ankaratip1945 @onkolojidernegi
https://t.co/F5lZU8slhO

[Cathy Russell @CathyRusGil]

Cardinal Health is proud to present Theranostics Week! Join us for a series of educational webinars dedicated to #theranostics and #nuclearmedicine. Register now at https://t.co/PmFZpD2Kxl.

[Brian Rini, MD @brian_rini]

Check out the live podcast on radioligands in prostate cancer from #UromigosLive 2023!

[Cardinal Health @cardinalhealth]

During this Breast Cancer Awareness Month, learn how innovative #radiopharmaceuticals are helping bring new hope to #cancer patients. https://t.co/qFgv9MazFF.

[GU Cast | Urology podcast! @gu_onc]

@DrMHofman brings #EANM23 @EANM_NucMed highlights live from Vienna on GU Cast. With guests @ProfKHerrmann @DrKerryJewell @FrancescoCeci13 @PhillipKooMD @declangmurphy and more https://t.co/tpLZduXtbK

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

Oral cavity cancer in young, non-smoking, and non-drinking patients: A... https://t.co/KM4njQcAOB
Nice work @JohnSunwooMD et al towards defining added subtypes of oral cancer

[Clare Schilling @ClareSchilling]

So happy to share thoughts with @DrJohndeAlmeida & Prof Stephen Lai at AHNS 2023, both leaders in SNB and lymphatic mapping studies in North America